Publication - Progress report

New Medicines Reviews 2013

Reports on the role of SMC & Review of IPTR & ADTC

SMC accepted medicine	Indication	Formulary decision & rationale for non-inclusion	Date
e.g. Everolimus (Afinitor)	Treatment of unresectable or metastatic, well- or moderately-differentiated neuroendocrine tumours of pancreatic origin in adults with progressive disease.	Not included - pending protocol	04/02/2013

There is a problem

Thanks for your feedback

Was this helpful?

Yes

Your comments

Your feedback helps us to improve this website. Do not give any personal information because we cannot reply to you directly.

Choose a reason for your feedback

Your comments

Your feedback helps us to improve this website. Do not give any personal information because we cannot reply to you directly.

Yes, but

Choose a reason for your feedback

Your comments

Your feedback helps us to improve this website. Do not give any personal information because we cannot reply to you directly.